BiVISTA

This study is investigating whether a new vaccine, SII TCV(B), can protect against Salmonella Paratypi A infection, a bacteria that causes typhoid and paratyphoid fever (also called ‘Enteric fever’). The study will also evaluate whether the new vaccine is safe, well tolerated and how the immune response compares to an existing, licensed typhoid vaccine.

Enteric fever causes people to feel generally unwell, sometimes with high fevers, headache, muscle and joint aches, abdominal pain and constipation.  There are approximately 13 million cases of Enteric fever every year. Typhoid and paratyphoid fever are both spread via the faeces of an infected person, usually via contaminated water or food. It is usually found in parts of the world where people don’t have access to clean water and sanitation. In severe cases, or left untreated, it can cause death.

Results from this study may be used for licensing of the SII TCV(B) vaccine. 

This study is led by the Oxford Vaccine Group and is taking place at several sites across England. Research for the Future is currently supporting recruitment at the following sites: North Manchester General Hospital